These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 30520977)
1. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977 [TBL] [Abstract][Full Text] [Related]
2. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F; Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial. Walls GM; Mistry H; Barlesi F; Bezjak A; Pechoux CL; O'Brien M; Van Meerbeeck JP; Blackhall F; Faivre-Finn C Int J Radiat Oncol Biol Phys; 2024 Aug; 119(5):1386-1390. PubMed ID: 38521132 [TBL] [Abstract][Full Text] [Related]
4. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218 [TBL] [Abstract][Full Text] [Related]
5. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial. Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy. Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Komaki R; Paulus R; Ettinger DS; Videtic GM; Bradley JD; Glisson BS; Langer CJ; Sause WT; Curran WJ; Choy H Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e531-6. PubMed ID: 22560543 [TBL] [Abstract][Full Text] [Related]
10. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342 [TBL] [Abstract][Full Text] [Related]
11. Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses. Hu X; Bao Y; Xu YJ; Zhu HN; Liu JS; Zhang L; Guo Y; Jin Y; Wang J; Ma HL; Xu XL; Song ZB; Tang HR; Peng F; Fang M; Kong Y; Chen MY; Dong BQ; Zhu L; Yu C; Yu XM; Hong W; Fan Y; Zhang YP; Chen PC; Zhao Q; Jiang YH; Zhou XM; Chen QX; Sun WY; Mao WM; Chen M Cancer; 2020 Feb; 126(4):840-849. PubMed ID: 31714592 [TBL] [Abstract][Full Text] [Related]
13. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer]. You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970 [TBL] [Abstract][Full Text] [Related]
14. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer. Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034 [TBL] [Abstract][Full Text] [Related]
15. Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial. Colaco R; Sheikh H; Lorigan P; Blackhall F; Hulse P; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C Lung Cancer; 2012 Apr; 76(1):72-7. PubMed ID: 22014897 [TBL] [Abstract][Full Text] [Related]
16. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Sheikh H; Colaco R; Lorigan P; Blackhall F; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C Lung Cancer; 2011 Oct; 74(1):75-9. PubMed ID: 21353720 [TBL] [Abstract][Full Text] [Related]
17. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789 [TBL] [Abstract][Full Text] [Related]
18. Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial. Yu TT; Hu X; Liufu WJ; Niu SQ; Lian HM; Ma HL; Wang J; Bao Y; Chen M; Peng F Cancer Med; 2024 Apr; 13(8):e7215. PubMed ID: 38659392 [TBL] [Abstract][Full Text] [Related]
19. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351 [TBL] [Abstract][Full Text] [Related]
20. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T; Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]